Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 21: | Line 21: | ||
|- | |- | ||
| Amgen | | Amgen | ||
| <div align=" | | <div align="center">14268</div> | ||
| Thousand Oaks, California | | Thousand Oaks, California | ||
| ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline | | ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline | ||
| Line 31: | Line 31: | ||
| <div align=" | | <div align="center">9284</div> | ||
| Line 39: | Line 39: | ||
| synthetic human insulin | | synthetic human insulin - their first famous product, many others produced using the Boyer-Cohen rDNA process | ||
| ? | | ? | ||
| Line 47: | Line 47: | ||
| <div align=" | | <div align="center">3187</div> | ||
| Line 63: | Line 63: | ||
| <div align=" | | <div align="center">3026</div> | ||
| Line 79: | Line 79: | ||
| <div align=" | | <div align="center">2683</div> | ||
| Line 95: | Line 95: | ||
| <div align=" | | <div align="center">1764</div> | ||
| Line 108: | Line 108: | ||
| <div align=" | | <div align="center">1277</div> | ||
| Line 121: | Line 121: | ||
| <div align=" | | <div align="center">899</div> | ||
| Line 137: | Line 137: | ||
| <div align=" | | <div align="center">766</div> | ||
| Line 153: | Line 153: | ||
| <div align=" | | <div align="center">678</div> | ||
Revision as of 12:13, 15 March 2009
Answer the questions:
- What are the 10 biggest for-profit companies in this field?
- How is the market distributed?
- Where are they located? Are there any incentives for specific locations?
- Correlate them with their main outputs (Data. Narratives. Tools)
- Understand and identify cases where these companies are “experimenting” or “adopting” commons-based approaches
- Identify these cases and treat them as entities that will also be placed in our mapping*device (the quadrants)
- Identify what companies are the “Microsofts” of the field and what companies are the “IBMs” of the field
| 2006 Revenue ($m) | Headquarters | Primary Outputs | Instances of Commons-based approaches
| |
| Amgen | 14268
|
Thousand Oaks, California | ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline | ? |
| Genentech
|
9284
|
South San Francisco
|
synthetic human insulin - their first famous product, many others produced using the Boyer-Cohen rDNA process | ? |
| Genzyme
|
3187
|
Cambridge, Massachusetts
|
Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue | ? |
| Gilead Sciences
|
3026
|
Foster City, California | 11 commercial products
|
? |
| Biogen Idec
|
2683
|
Cambridge, Massachusetts
|
Treatments for Crohn's disease, non-Hodgkin's lymphoma, and multiple sclerosis | ? |
| Cephalon
|
1764
|
Frazer, Pennsylvania | Specializes in treating neurodegenerative diseases | ? |
| MedImmune
|
1277
|
Gaithersburg, Maryland | Only major drug prevents respiratory diseases in infants | ? |
| Celgene
|
899
|
Summit, New Jersey
|
treatments for erythema nodosum leprosum ("ENL") and multiple myeloma | ? |
| Abraxis BioScience
|
766
|
Los Angeles, California
|
uses patented nanoparticle technology to produce products for metastatic breast cancer | ? |
| ImClone Systems
|
678
|
New York, New York
|
acquired by Eli Lilly, tried to produce Erbitux for Colorectal Cancer, but failed to win FDA approval | ? |